发明名称 |
Stabilized liquid anti-RSV antibody formulations |
摘要 |
The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention. |
申请公布号 |
US9272032(B2) |
申请公布日期 |
2016.03.01 |
申请号 |
US201414554804 |
申请日期 |
2014.11.26 |
申请人 |
MedImmune, LLC |
发明人 |
Oliver Cynthia N.;Shane Erica;Isaacs Benjamin S.;Allan Christian B.;Chang Stephen T. |
分类号 |
A61K39/395;A61K39/42;A61K9/00;A61K47/18;A61K47/26;C07K16/00;C07K16/10;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
Mueting, Raasch & Gebhardt, P.A. |
代理人 |
Mueting, Raasch & Gebhardt, P.A. |
主权项 |
1. A method of preventing, treating or ameliorating one or more symptoms associated with a RSV infection in a subject, said method comprising administering a prophylactically or therapeutically effective amount of a liquid palivizumab formulation, said formulation comprising in an aqueous carrier: (a) at least 15 mg/ml of palivizumab, or an antigen-binding fragment thereof; and (b) histidine at a concentration of about 1 mM to about 100 mM, wherein said formulation is substantially free of surfactant, inorganic salts or other excipients. |
地址 |
Gaithersburg MD US |